Methodological validation of Miro1 retention as a candidate Parkinson’s disease biomarker

Mitochondrial markers help stratify Parkinson's disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.

Authors

Institutions

Publication Details

Journal
npj Parkinson s Disease
Published
2025-09-15
DOI
https://doi.org/10.1038/s41531-025-01115-8
Citations
1
Primary Topic
RNA regulation and disease
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Methodological validation of Miro1 retention as a candidate Parkinson’s disease biomarker

Kathrin Brockmann, Daniel Merk, Julia C. Fitzgerald, Patrick May et al.
1 citations
npj Parkinson s Disease
RNA regulation and disease
0.81
article

Methodological validation of Miro1 retention as a candidate Parkinson’s disease biomarker

Kathrin Brockmann, Daniel Merk, Julia C. Fitzgerald, Patrick May, Christian Johannes Gloeckner, Richard Wüst, Giuseppe Arena, Vyron Gorgogietas, Thomas Gasser, Daniele Ferrante, Anne Grünewald, Layla Drwesh, Rejko Krüger
article en
1 citations

Abstract

Mitochondrial markers help stratify Parkinson's disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.

npj Parkinson s DiseaseVol. 11(1)
Centre Hospitalier de Luxembourg (LU), University of Luxembourg (LU), German Center for Neurodegenerative Diseases (DE), Luxembourg Institute of Health (LU), University Children's Hospital Tübingen (DE), Hertie Institute for Clinical Brain Research (DE), University of Tübingen (DE)
Michael J. Fox Foundation for Parkinson's Research, Eberhard Karls Universität Tübingen, National Institute of Neurological Disorders and Stroke
Openalex Percentile: Top 24%
RNA regulation and disease
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.